| ALL ORDERS MUST BE SIGNED,   | DATED AND TIMED BY PHYSICIAN   |  |  |  |
|--|--|--|--|--|
| Allergies/Reactions: Fax all infusions to: 8 Please mark the apprint infusion center:  |  |  |  |  |
| ORDERS WITH CHECK BOXES When an order is optional (those w   | th check boxes), physicians are responsible for indicating a check mark in the                                 |  |  |  |
| box next to the order. Orders left unchecked will not be initiated.  |  |  |  |  |
| Agalsidase Beta (Fabrazyme)  |  |  |  |  |
| Patient Name:  | Requested Date of Service: / /   |  |  |  |
| Date of Birth: / / Patient Phone Nu  | nber: ( ) 🖵 May leave message  |  |  |  |
|  | ICD -10 Code:  |  |  |  |
| Diagnosis: 🗅 Fabry Disease   | •  |  |  |  |
|  |  |  |  |  |
| <b>Required:</b> H&P with documentation to support above diagnosis in  | cluding ICD-10 code and supporting labs<br>treatment will be delayed until complete information is available** |  |  |  |
| in required documentation not received with order, scheduling of   | treatment will be delayed until complete information is available  |  |  |  |
| IV Access: Access and/or maintain IV site in accordance with MHS IV Therapy P&P: Peripheral IV Device Site Selection, Insertion,<br>Maintenance, and Discontinuation; and Maintenance of Central Venous Catheters-Flushing, Dressing Changes and Removal.  |  |  |  |  |
| Maintenance, and Discontinuation; and Maintenance of Centra  | i venous Catheters-Flushing, Dressing Changes and Removal.   |  |  |  |
| Patient weight lb/kg (required)  |  |  |  |  |
| Treatment Regimen:   |  |  |  |  |
| <ul> <li>Pre-meds given prior to infusion:</li> <li>Acetaminophen 650 mg po x 1 dose</li> </ul>  |  |  |  |  |
|  |  |  |  |  |
| Agalsidase Beta (Fabrazyme): Administered IV in NS with 0.22 micron filter<br>Patient wgt = 35 kg = 50 ml TV; 35.1-70 kg = 100 ml; 70.1-100 kg = 250 ml TV; 100 mg = 500 m TV</td  |  |  |  |  |
| I mg/kg =mg IV every 2 weeks x months (up to 12 months)  |  |  |  |  |
| <b>Infusion Rate:</b> For patients >/= 30 kg: Infusion should be initiated at a rate of 15 mg/hour; after tolerance to initial infusion rate is established, the infusion rate may be increased in incements of 3 to 5 mg/hour with each subsequent infusions. Administration duration: $\geq$ 1.5 hours (based upon individual tolerability). |  |  |  |  |
| ✓ Vital Signs: Check vital signs prior to and at completion of infusion.<br>Contact provider if systolic BP >180; diastolic BP >100; systolic BP <90; HR >110; temp >38C (100.4F)  |  |  |  |  |
| <ul> <li>If hypersensitivity develops (fever, chills, hypotension, rigors, itching, rash, etc.):</li> <li>Consult MultiCare hypersensitivity guideline for treatment management</li> <li>Notify provider of reaction, assessment and need for futher orders</li> </ul>   |  |  |  |  |
| Code Status: Please note, patients will be considered FULL Code unless marked otherwise. If the patient has a POLST, advance directive or living will, please include a copy with the orders.  |  |  |  |  |
| Was consent obtained: 🗆 Yes 🕒 No (if yes, please send DOCUMENTATION of consent with order)   |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| Provider Signature Print Name  | Date Time  |  |  |  |
| Another brand of drug, identical in form and content, may be dispensed ur  | less checked  Orders expire in 12 months**   |  |  |  |
| Patient Identification - Always Attach Patient Label   | Pre-printed Order  |  |  |  |
| Name:  | AGALSIDASE BETA (Fabrazyme)  |  |  |  |
| MRN #:   |  |  |  |  |
| CSN #:   | MultiCare 🚮  |  |  |  |
| Age / Sex and Gender:  | 1 IIII IIII IIII IIIII IIIII IIIII IIII IIII   |  |  |  |

| Aae  | /Sex  | and | Gender |
|------|-------|-----|--------|
| Ayc. | 1 300 | ana | Genaer |